GVK Bio has announced the signing of a definitive agreement to acquire Vanta Bioscience.
Commenting on the acquisition, Manni Kantipudi, CEO, GVK BIO, said: “The acquisition is in line with our business strategy of being an integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology.”
The Hyderabad-based company did not disclose the financials of the acquisition. Vanta Bioscience is a contract research organisation. The company offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries. Vanta Bioscience also offers toxicology services using alternative methods for the cosmetics industry.
Gerard Schwickerath, Vice-President and General Manager, Vanta Bioscience said: The company will continue doing its core activity under the direction of GVK BIO and provide further opportunities to our clients and staff. Business Line
